Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by NanoViricides, Inc. on December 7, 2024. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol NNVC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A quorum was established with 47.1% of outstanding voting capital stock present. Shareholders approved two key proposals:
- Proposal 1: Election of Directors
- Theodore E. Rokita (Class I): Approved with 2,060,147 votes For vs. 166,389 Against.
- Makarand Jawadekar (Class II): Approved with 1,951,381 votes For vs. 272,416 Against.
- Brian Zucker (Class II): Approved with 2,088,483 votes For vs. 139,413 Against.
- All directors were elected to two-year terms expiring at the 2026 annual meeting.
- Proposal 2: Ratification of Accounting Firm
- EisnerAmper, LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2025.
- Votes: 5,757,913 For, 230,937 Against, 107,209 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the Proxy Statement filed on October 15, 2024.
Investor Verification Checklist
- Verify the full text of the Proxy Statement (filed October 15, 2024) for detailed biographies of the newly elected directors and the rationale for the accounting firm selection.
- Confirm the total number of outstanding shares to contextualize the 47.1% quorum participation rate.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.